<DOC>
	<DOCNO>NCT01653756</DOCNO>
	<brief_summary>The purpose study examine effect multi-dose regimen IPI-145 lung function mild asthmatic subject follow allergen challenge .</brief_summary>
	<brief_title>A Phase 2a , Efficacy Safety Study Duvelisib Mild Asthmatic Subjects</brief_title>
	<detailed_description>This phase 2a , randomize , double-blind , placebo-controlled , multi-dose , 2-way cross-over study design examine effect IPI-145 lung function inflammatory index mild , allergen-reactive asthmatic subject undergo allergen challenge .</detailed_description>
	<criteria>Male female adult 18 60 year age Diagnosis asthma ( mild ) least 6 month prior Screening Forced expiratory volume one second ( FEV1 ) ≥70 % predict value Screening A positive skin prick test test allergen Any prior treatment phosphoinositide3kinase ( PI3K ) inhibitor IPI145 previous clinical study Acute asthma exacerbation within 6 week prior Screening Use medication treatment asthma shortacting β2 agonist ( need ) within 4 week prior Screening Participation another clinical study within minimum 30 day prior study Screening A positive screen result active latent tuberculosis A history cardiovascular disease The concomitant use acidreducing agent cholinesterase inhibit medication Inadequate hepatic function define Aspartate Aminotransferase ( AST ) and/or Alanine Aminotransferase ( ALT ) great 1.5 time great limit normal ( ULN ) Inadequate renal function define serum creatinine great 2.0 milligrams/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergen Challenge</keyword>
</DOC>